Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swedish Doubts About Avodart Sink Prostate Cancer Prevention Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline halts global pursuit of a prostate cancer risk reduction claim for its 5-alpha reductase inhibitor dutasteride after Swedish regulators echo FDA concerns about clinical benefit and safety.

You may also be interested in...



GSK Loses Bid For Avodart Prostate Cancer Prevention Indication

FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.

Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee

Reducing the risk of low-grade prostate cancers that may not affect a patient's health isn't worth the risk of increasing the numbers of high-grade tumors, ODAC says.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel